Total Payments
$6,812
2024 Payments
$109.48
Companies
9
Transactions
28
Medicare Patients
1,250
Medicare Billing
$98,012
Payment Breakdown by Category
Consulting$4,335 (63.6%)
Food & Beverage$2,434 (35.7%)
Travel$33.79 (0.5%)
Education$8.62 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $4,335 | 3 | 63.6% |
| Food and Beverage | $2,434 | 23 | 35.7% |
| Travel and Lodging | $33.79 | 1 | 0.5% |
| Education | $8.62 | 1 | 0.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novo Nordisk Inc | $5,110 | 12 | $0 (2022) |
| Amgen Inc. | $562.16 | 6 | $0 (2019) |
| E.R. Squibb & Sons, L.L.C. | $422.80 | 3 | $0 (2023) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $177.36 | 2 | $0 (2019) |
| GENZYME CORPORATION | $121.32 | 1 | $0 (2021) |
| Novartis Pharmaceuticals Corporation | $115.42 | 1 | $0 (2018) |
| Regeneron Healthcare Solutions, Inc. | $110.00 | 1 | $0 (2022) |
| JAZZ PHARMACEUTICALS INC. | $109.48 | 1 | $0 (2024) |
| Alkermes, Inc. | $83.29 | 1 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $109.48 | 1 | JAZZ PHARMACEUTICALS INC. ($109.48) |
| 2023 | $184.62 | 1 | E.R. Squibb & Sons, L.L.C. ($184.62) |
| 2022 | $391.65 | 4 | Novo Nordisk Inc ($198.36) |
| 2021 | $2,161 | 3 | Novo Nordisk Inc ($2,040) |
| 2019 | $518.12 | 5 | Amgen Inc. ($348.14) |
| 2018 | $2,931 | 8 | Novo Nordisk Inc ($2,590) |
| 2017 | $515.44 | 6 | Novo Nordisk Inc ($221.26) |
All Payment Transactions
28 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 01/24/2024 | JAZZ PHARMACEUTICALS INC. | ZEPZELCA (Drug) | Food and Beverage | In-kind items and services | $109.48 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 03/02/2023 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $184.62 | General |
| 03/23/2022 | Novo Nordisk Inc | Ozempic (Drug) | Food and Beverage | In-kind items and services | $73.36 | General |
| Category: Diabetes | ||||||
| 03/22/2022 | Alkermes, Inc. | VIVITROL (Drug) | Food and Beverage | In-kind items and services | $83.29 | General |
| Category: CNS | ||||||
| 03/08/2022 | Novo Nordisk Inc | Rybelsus (Drug) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: Diabetes | ||||||
| 02/24/2022 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Food and Beverage | In-kind items and services | $110.00 | General |
| Category: ONCOLOGY | ||||||
| 11/29/2021 | GENZYME CORPORATION | LIBTAYO (Biological) | Food and Beverage | In-kind items and services | $121.32 | General |
| Category: Oncology | ||||||
| 04/29/2021 | Novo Nordisk Inc | RYBELSUS (Drug) | Consulting Fee | Cash or cash equivalent | $1,020.00 | General |
| Category: Diabetes | ||||||
| 04/28/2021 | Novo Nordisk Inc | RYBELSUS (Drug) | Consulting Fee | Cash or cash equivalent | $1,020.00 | General |
| Category: Diabetes | ||||||
| 08/22/2019 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $109.95 | General |
| 06/04/2019 | Amgen Inc. | EVENITY (Biological) | Food and Beverage | In-kind items and services | $109.73 | General |
| Category: Bone Health | ||||||
| 05/23/2019 | Amgen Inc. | EVENITY (Biological) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: Bone Health | ||||||
| 05/01/2019 | Novo Nordisk Inc | Ozempic (Drug) | Food and Beverage | In-kind items and services | $60.03 | General |
| Category: Diabetes | ||||||
| 02/26/2019 | Amgen Inc. | Prolia (Biological) | Food and Beverage | In-kind items and services | $113.41 | General |
| Category: Bone Health | ||||||
| 11/29/2018 | Novo Nordisk Inc | Victoza (Drug) | Consulting Fee | Cash or cash equivalent | $2,295.00 | General |
| Category: Diabetes | ||||||
| 11/29/2018 | Novo Nordisk Inc | Victoza (Drug) | Food and Beverage | In-kind items and services | $122.07 | General |
| Category: Diabetes | ||||||
| 11/29/2018 | Novo Nordisk Inc | Victoza (Drug) | Travel and Lodging | In-kind items and services | $33.79 | General |
| Category: Diabetes | ||||||
| 11/13/2018 | Amgen Inc. | Aimovig (Biological) | Food and Beverage | In-kind items and services | $104.31 | General |
| Category: Neuroscience | ||||||
| 09/18/2018 | Novo Nordisk Inc | Tresiba (Drug) | Food and Beverage | In-kind items and services | $76.13 | General |
| Category: Diabetes | ||||||
| 08/10/2018 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $121.12 | General |
| 04/26/2018 | Novo Nordisk Inc | Ozempic (Drug) | Food and Beverage | In-kind items and services | $63.30 | General |
| Category: Diabetes | ||||||
| 04/18/2018 | Novartis Pharmaceuticals Corporation | — | Food and Beverage | In-kind items and services | $115.42 | General |
| 06/13/2017 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $117.06 | General |
| 06/07/2017 | Amgen Inc. | — | Education | In-kind items and services | $8.62 | General |
| 06/06/2017 | Amgen Inc. | Prolia (Biological) | Food and Beverage | In-kind items and services | $101.09 | General |
| Category: Endocrinology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 5 | 136 | 180 | $41,709 | $11,633 |
| 2022 | 5 | 234 | 303 | $73,825 | $19,117 |
| 2021 | 8 | 359 | 463 | $112,881 | $31,881 |
| 2020 | 10 | 521 | 652 | $134,110 | $35,381 |
Total Patients
1,250
Total Services
1,598
Medicare Billing
$98,012
Procedure Codes
28
All Medicare Procedures & Services
28 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 53 | 56 | $16,812 | $3,127 | 18.6% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 18 | 33 | $8,581 | $3,121 | 36.4% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 24 | 49 | $8,103 | $3,116 | 38.5% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2023 | 21 | 21 | $3,727 | $1,367 | 36.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 20 | 21 | $4,486 | $901.34 | 20.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 167 | 199 | $52,123 | $12,227 | 23.5% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 11 | 31 | $7,659 | $2,647 | 34.6% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 16 | 33 | $5,553 | $1,939 | 34.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 29 | 29 | $5,498 | $1,327 | 24.1% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2022 | 11 | 11 | $2,992 | $978.35 | 32.7% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 201 | 272 | $69,360 | $18,421 | 26.6% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 29 | 33 | $11,352 | $3,030 | 26.7% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 12 | 13 | $6,318 | $2,023 | 32.0% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Office | 2021 | 37 | 40 | $4,617 | $1,996 | 43.2% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 12 | 22 | $5,500 | $1,846 | 33.6% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 40 | 40 | $6,880 | $1,735 | 25.2% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 14 | 29 | $5,046 | $1,634 | 32.4% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2021 | 14 | 14 | $3,808 | $1,195 | 31.4% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 185 | 237 | $60,435 | $11,399 | 18.9% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Office | 2020 | 131 | 158 | $18,012 | $8,692 | 48.3% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 18 | 22 | $10,692 | $3,321 | 31.1% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 33 | 35 | $12,040 | $2,558 | 21.2% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 22 | 48 | $8,352 | $2,441 | 29.2% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 11 | 23 | $5,750 | $1,881 | 32.7% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Office | 2020 | 44 | 51 | $3,723 | $1,789 | 48.1% |
About Dr. Lynn Bowlby, MD
Dr. Lynn Bowlby, MD is a Internal Medicine healthcare provider based in Providence, Rhode Island. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/28/2006. The National Provider Identifier (NPI) number assigned to this provider is 1588611123.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Lynn Bowlby, MD has received a total of $6,812 in payments from pharmaceutical and medical device companies, with $109.48 received in 2024. These payments were reported across 28 transactions from 9 companies. The most common payment nature is "Consulting Fee" ($4,335).
As a Medicare-enrolled provider, Bowlby has provided services to 1,250 Medicare beneficiaries, totaling 1,598 services with total Medicare billing of $98,012. Data is available for 4 years (2020–2023), covering 28 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Other Specialties Internal Medicine
- Location Providence, RI
- Active Since 05/28/2006
- Last Updated 11/20/2024
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1588611123
Products in Payments
- Victoza (Drug) $2,578
- RYBELSUS (Drug) $2,040
- EVENITY (Biological) $234.73
- LIBTAYO (Biological) $231.32
- Prolia (Biological) $214.50
- Ozempic (Drug) $196.69
- Tresiba (Drug) $170.72
- Rybelsus (Drug) $125.00
- ZEPZELCA (Drug) $109.48
- Aimovig (Biological) $104.31
- VIVITROL (Drug) $83.29
- JARDIANCE (Drug) $67.41
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Providence
Randall Ingham, M.d, M.D
Internal Medicine — Payments: $154,470
Internal Medicine $154,470
Farah Moustafa, Md, MD
Internal Medicine — Payments: $50,984
Internal Medicine $50,984
Monica Dhakar, M.d, M.D
Internal Medicine — Payments: $47,405
Internal Medicine $47,405
Hajra Awwab, Md, MD
Internal Medicine — Payments: $41,418
Internal Medicine $41,418
Richard Ruggieri, M.d, M.D
Internal Medicine — Payments: $36,352
Internal Medicine $36,352
Dr. Peter Barth, M.d, M.D
Internal Medicine — Payments: $29,192
Internal Medicine $29,192